Integrated Analysis Reveals Critical Cisplatin-resistance Regulators E2F7 Contributed to Tumor Progression and Metastasis in Lung Adenocarcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 May 17

PMID 38760774

Authors

Xiaomin Mao

Shumin Xu

Huan Wang

Peng Xiao

Shumin Li

Jiaji Wu

Junhui Sun

Cheng Jin

Mo Shen

Yueli Shi

Bufu Tang

Ying Yang

Weiyu Chen

Zhiyong Xu

Yun Xu

Affiliations

Soon will be listed here.

Abstract

Background: Drug resistance poses a significant challenge in cancer treatment, particularly as a leading cause of therapy failure. Cisplatin, the primary drug for lung adenocarcinoma (LUAD) chemotherapy, shows effective treatment outcomes. However, the development of resistance against cisplatin is a major obstacle. Therefore, identifying genes resistant to cisplatin and adopting personalized treatment could significantly improve patient outcomes.

Methods: By examining transcriptome data of cisplatin-resistant LUAD cells from the GEO database, 181 genes associated with cisplatin resistance were identified. Using univariate regression analysis, random forest and multivariate regression analyses, two prognostic genes, E2F7 and FAM83A, were identified. This study developed a prognostic model utilizing E2F7 and FAM83A as key indicators. The Cell Counting Kit 8 assay, Transwell assay, and flow cytometry were used to detect the effects of E2F7 on the proliferation, migration, invasiveness and apoptosis of A549/PC9 cells. Western blotting was used to determine the effect of E2F7 on AKT/mTOR signaling pathway.

Results: This study has pinpointed two crucial genes associated with cisplatin resistance, E2F7 and FAM83A, and developed a comprehensive model to assist in the diagnosis, prognosis, and evaluation of relapse risk in LUAD. Analysis revealed that patients at higher risk, according to these genetic markers, had elevated levels of immune checkpoints (PD-L1 and PD-L2). The prognostic and diagnosis values of E2F7 and FAM83A were further confirmed in clinical data. Furthermore, inhibiting E2F7 in lung cancer cells markedly reduced their proliferation, migration, invasion, and increased apoptosis. In vivo experiments corroborated these findings, showing reduced tumor growth and lung metastasis upon E2F7 suppression in lung cancer models.

Conclusion: Our study affirms the prognostic value of a model based on two DEGs, offering a reliable method for predicting the success of tumor immunotherapy in patients with LUAD. The diagnostic and predictive model based on these genes demonstrates excellent performance. In vitro, reducing E2F7 levels shows antitumor effects by blocking LUAD growth and progression. Further investigation into the molecular mechanisms has highlighted E2F7's effect on the AKT/mTOR signaling pathway, underscoring its therapeutic potential. In the era of personalized medicine, this DEG-based model promises to guide clinical practice.

Citing Articles

Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC.

Bafiti V, Thanou E, Ouzounis S, Kotsakis A, Georgoulias V, Lianidou E Cancers (Basel). 2024; 16(22).

PMID: 39594687 PMC: 11592109. DOI: 10.3390/cancers16223729.

References

Khan T, Srivastava N, Srivastava A, Sareen A, Mathur R, Chande A . SHP-1 plays a crucial role in CD40 signaling reciprocity. J Immunol. 2014; 193(7):3644-53. DOI: 10.4049/jimmunol.1400620. View

Xu K, Ma J, Hall S, Peng R, Yang H, Yao F . Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks. Theranostics. 2023; 13(2):704-723. PMC: 9830441. DOI: 10.7150/thno.80184. View

Wang Y, Wo Y, Lu T, Sun X, Liu A, Dong Y . Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression. Transl Lung Cancer Res. 2021; 10(1):57-70. PMC: 7867743. DOI: 10.21037/tlcr-20-1062. View

Shi Y, Xu Y, Xu Z, Wang H, Zhang J, Wu Y . TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. Cancer Lett. 2022; 532:215583. DOI: 10.1016/j.canlet.2022.215583. View

Richtmann S, Wilkens D, Warth A, Lasitschka F, Winter H, Christopoulos P . FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC. Cancers (Basel). 2019; 11(5). PMC: 6562954. DOI: 10.3390/cancers11050652. View

John A, Popat S . Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?. Ann Oncol. 2023; 34(10):829-830. DOI: 10.1016/j.annonc.2023.06.010. View

Tan Y, Li J, Zhao G, Huang K, Cardenas H, Wang Y . Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022; 13(1):4554. PMC: 9356138. DOI: 10.1038/s41467-022-32101-w. View

Kehl K, Jaklitsch M . Quality Surgical Care and Outcomes for Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2023; 41(20):3580-3583. DOI: 10.1200/JCO.23.00745. View

Pan C, Kang J, Hwang J, Li J, Boese A, Wang X . Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nat Commun. 2021; 12(1):4960. PMC: 8368102. DOI: 10.1038/s41467-021-24845-8. View

10.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

11.

Aleshin V, Zhou X, Krishnan S, Karlsson A, Bunik V . Interplay Between Thiamine and p53/p21 Axes Affects Antiproliferative Action of Cisplatin in Lung Adenocarcinoma Cells by Changing Metabolism of 2-Oxoglutarate/Glutamate. Front Genet. 2021; 12:658446. PMC: 8047112. DOI: 10.3389/fgene.2021.658446. View

12.

Delasos L, Madabhushi A, Patil P . Can Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?. J Thorac Oncol. 2023; 18(6):686-688. DOI: 10.1016/j.jtho.2023.03.011. View

13.

Huang H, Yang C, Zhang Q, Zhuo T, Li X, Li N . Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression. Bioengineered. 2022; 13(3):4964-4977. PMC: 8973779. DOI: 10.1080/21655979.2022.2037871. View

14.

Sui Q, Chen Z, Hu Z, Huang Y, Liang J, Bi G . Cisplatin resistance-related multi-omics differences and the establishment of machine learning models. J Transl Med. 2022; 20(1):171. PMC: 9004122. DOI: 10.1186/s12967-022-03372-0. View

15.

Wu Z, Su J, Li F, Chen T, Mayner J, Engler A . YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. Nat Commun. 2023; 14(1):5916. PMC: 10516997. DOI: 10.1038/s41467-023-41585-z. View

16.

Zhang X, Kiapour N, Kapoor S, Khan T, Thamilarasan M, Tao Y . IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Immunol. 2019; 203(5):1142-1150. PMC: 6697738. DOI: 10.4049/jimmunol.1900311. View

17.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

18.

Zhang F, Guo C, Cao X, Yan Y, Zhang J, Lv S . Gastric cancer cell-derived extracellular vesicles elevate E2F7 expression and activate the MAPK/ERK signaling to promote peritoneal metastasis through the delivery of SNHG12. Cell Death Discov. 2022; 8(1):164. PMC: 8983762. DOI: 10.1038/s41420-022-00925-6. View

19.

Lovly C . Perioperative Immunotherapy - A KEY toward Improved Outcomes for Early-Stage Lung Cancer?. N Engl J Med. 2023; 389(6):560-561. DOI: 10.1056/NEJMe2305762. View

20.

Hu H, Wang F, Wang M, Liu Y, Wu H, Chen X . FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Int J Med Sci. 2020; 17(6):807-814. PMC: 7085261. DOI: 10.7150/ijms.33992. View